PerkinElmer Brings Advanced Newborn Screening Technology to China | Stories | PerkinElmer
珀金埃尔默网站上的Cookie
珀金埃尔默使用cookies来确保我们为您提供在我们网站上的最佳体验。 这可能包括来自第三方网站的cookies。 如果您不改变您的设置点击继续,我们会认为您同意接收本网站的cookies。 您可以随时更改您的Cookie设置。 要了解更多信息,请查看我们的Cookie政策,其中包含有关如何管理Cookie的信息。

PerkinElmer Brings Advanced Newborn Screening Technology to China

August 21, 2015

Innovative solutions helping newborn screening labs in China

Background

About the only people busier than enumerators in China may be the doctors and midwives who are responsible for delivering an estimated 17 million newborns across this vast country in 2015.1 To put that into proper perspective, that number totals over 5% of the entire U.S. population and more than 3% of all of Europe…and that is just this year. With over 1.35 billion people and an estimated birth defect rate of between 4% – 6%, Chinese officials are working hard to improve and expand the efficiency of the country’s newborn screening programs.2

An Expanding Collaboration

In 2014, China's National Health and Family Planning Commission announced an exclusive, three-year collaboration with global life and environmental sciences company PerkinElmer to develop and implement an extensive newborn screening training initiative. Leveraging the company’s diagnostic technologies and expertise, more than 3,000 Chinese doctors, clinicians, and laboratory technicians across 600 rural counties are currently being trained in sample collection, clinical diagnostics and treatment, as well as site inspection and overall program management of China’s rapidly expanding newborn screening initiative. In addition, the company is working with the National Maternal and Children Health Surveillance Office to implement early detection of life-threatening disorders in newborns, including phenylketonuria, which can damage the central nervous system and the brain, and congenital hypothyroidism. In the past few years, PerkinElmer has also screened more than nine million babies in the country for hypothyroidism and many other disorders.3

Most health officials would cheer such a high volume of newborn screenings as a remarkable achievement. While indeed it is, the Chinese see it as a promising start to an immense initiative that values efficiency, quality, and healthy outcomes.

In April, 2015, the Chinese Food and Drug Administration (CFDA) approved PerkinElmer’s request to market its Genetic Screening Processor® (GSP) instrument and GSP Neonatal hTSH reagent kit to test for hyperthyroidism in newborns throughout the country. The GSP instrument is a fully automated analyzer that allows up to 26 96-well-plates that can be tested simultaneously for a variety of disorders using the company’s dried bloodspot testing technology.4

Planning Ahead With a Global Leader

China began its newborn screening program in 1981. This year, Chinese officials estimate that nearly 80% of newborns will be tested and that number will increase in the years ahead.5 Currently, the more advanced areas of the country test for more than 30 genetic disorders, but screening programs vary across China’s 30 provinces.6

“We are committed to developing innovative solutions to help newborn screening labs in China respond to rising birth rates and expand access to testing for serious health risks in newborn babies,” Johnson Zhang, PerkinElmer’s vice president and general manager for Asia-Pacific diagnostics, says. “As China seeks to improve the efficiency of newborn screening and reduce false-positive and false-negative rates, our advanced detection technologies are designed to deliver highly reliable results for better outcomes.”7

PerkinElmer is the world's largest producer of newborn screening tests, as well as sample collection devices, sample preparation and measuring instruments, and informatics to support the entire screening process from collection of the sample to follow-up of the screened baby. To date, the company has screened some 486 million babies worldwide and is involved in approximately 80% of China’s 218 neonatal screening centers.8

  1. Big national birthrate rise signals new peak, China Daily.
  2. Birth defects surveillance in China, World Journal of Pediatrics.
  3. PerkinElmer Launches Newborn Screening Program in China, Genetic Engineering & Biotechnology News.
  4. PerkinElmer Genetic Screening Processor.
  5. Newborn screening and related policy against Phenylketonuria in China, Intractable Rare Dis Res. 2013 Aug; 2(3): 72–76.
  6. The profile of newborn screening coverage in China, J Med Screen. December 2009 vol. 16no. 4 163–166.
  7. PerkinElmer Launches First Fully Automated Genetic Disorder Screening System in China, PerkinElmer.
  8. Ibid.

更多故事关于 新闻, 诊断, 检测, 新生儿筛查

珀金埃尔默携生物大分子制药方案亮相2018生物制品年会

中国生物制品年会作为学界一年一度最重要的活动,引起了广泛的行业关注。今年生物制品年会于11月15-16日在气候宜人的“春城”昆明举行,本次活动围绕“新型生物技术药研发与评价”、“新型疫苗研发与评价”、“基因与细胞治疗研发与评价”、“生物制药投融资”、“生物制药工程与数字信息化”展开,为2000余位参会代表带来近100场主...

珀金埃尔默在analytica China 2018上载誉归来

经过三天的热闹与相聚,慕尼黑(上海)生化分析展于11月2日落下帷幕。珀金埃尔默展出的仪器覆盖原子光谱、色谱、材料表征、联用技术、生命科学等产品线。除此之外,还有众多行业解决方案、OneSource一站式实验室服务、试剂与耗材等配套服务。

感谢有你——再聚慕尼黑分析生化展

此次珀金埃尔默在慕尼黑生化展上展出了ICP-MS NexIon 2000, ICP-OES Avio 500,高内涵分析系统Operetta CLS及新品荧光分光光度计FL 6500等共计10余台仪器。

珀金埃尔默推出QSight®400系列三重四极杆质谱仪

美国拉斯维加斯大麻商业展览会——致力于创建更健康世界的全球领先企业珀金埃尔默日前宣布推出QSight®400系列三重四极杆质谱仪。这是一款高灵敏度分析仪器,专门用于快速测定和定量复杂食品、大麻和环境测试中的杀虫剂、真菌毒素和新型污染物。

历久弥新珀金埃尔默发布两款质谱新品,闪耀中国质谱学术大会

2018年中国质谱学术大会(CMSC 2018)在广州东方宾馆隆重开幕。来自十多个国家地区的质谱技术与应用方面的专家学者、厂商及相关用户共1900余人参加了本次会议。珀金埃尔默作为本次大会的白金赞助商,全程倾情参与了此次大会。